事项:2025 年3 月19 日,和黄医药公布2024 年年度业绩。公司实现总收入6.30 亿美元(按固定汇率计算-24%),其中肿瘤产品综合收入为2.715 亿美元(+67%,按固定汇率计算,下同),来自武田的首付款、监管里程碑及研发服务收入相较2023 年的3.459 亿美元减少至6,700 万美元。公司实现年净收益3770 万美元,于2024 年12 月31 日的现金余额为8.361 亿美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.